Record Details

Method Developments and Validation of Atorvastatin and Clopidogrel in Tablet dosage form by Miceller Liquid Chromatography

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Method Developments and Validation of Atorvastatin and Clopidogrel in Tablet dosage form by Miceller Liquid Chromatography
 
Creator Kumar, Manoj
Pradhan, Subhalaxmi
 
Subject Cardiac drugs
Critical micellar concentration
Reversed phase liquid chromatography
SDS
Surfactants
 
Description 1250-1256
To avoid heart attacks and strokes, a combination of atorvastatin and clopidogrel is used. A cholesterol-producing enzyme is
inhibited by the lipid-lowering medication atorvastatin. Atorvastatin helps in reducing the level of bad cholesterol, Low Density
Lipoprotein (LDL) and increasing good cholesterol level, High Density Lipoprotein (HDL) in our body. An antiplatelet drug
called clopidogrel reduces the risk of dangerous blood clots by preventing platelets from adhering to one another. A novel,
straightforward, and precise approach was used to estimate atorvastatin and clopidogrel quantitatively in tablet formulation by
Micellar Liquid Chromatography (MLC). The MLC is a green and eco-friendly technique in Chromatography where surfactant
solutions played the role as the eluent above the Critical Miceller Concentration (CMC).The separation of drug formulation was
carried out by Reversed Phase Liquid Chromatography (RP-HPLC) using a Deoxyprobe C18 column (4.6 × 250 mm, 5 μm)
with a mobile phase that contained 0.12M SDS and 10% Propanol-2 at a pH 3.7 maintained by o-Phosphoric Acid.
The separation was performed at room temperature with an elution rate of 1.1mL/minat 220 nm. The retention time of
atorvastatin is 2.3 while that of clopidogrel is 3.9 min. According to the schedule V of the drug and Cosmetic Act, the
percentage composition of the sample under analysis ranged from 90 to 110%. The suggested procedure was in agreement with
ICH requirements. In addition, the method was easy to use, affordable, safe, and non-harmful to the environment. It can be used
for repetitive measurable estimation of atorvastatin and clopidogrel in tablets.
 
Date 2023-12-29T12:19:15Z
2023-12-29T12:19:15Z
2023-12
 
Type Article
 
Identifier 0022-4456 (Print); 0975-1084 (Online)
http://nopr.niscpr.res.in/handle/123456789/63137
https://doi.org/0.56042/jsir.v82i12.1767
 
Language en
 
Publisher NIScPR-CSIR, India
 
Source JSIR Vol.82(11) [November 2023]